- What you will discover...
- Epidiolex is used to treat refractory childhood-onset epilepsy and is expected to launch in 2020.
- GW Pharma’s Sativex is approved for muscle spasticity in patients suffering from multiple sclerosis in Europe, and is currently at the pre-registration stage in the US.
- Dravet syndrome and Lennox-Gastaut syndrome can cause hundreds of seizures a fortnight for sufferers; medical marijuana treatments focus on conditions such as these.
Be at the forefront of the medical marijuana market...
There are five approved medical marijuana treatments – Epidiolex, Marinol, Sativex, Nabilone and Syndros – in the countries discussed in this report (the US, France, Germany, Italy, Spain, the UK, Canada, Israel, and Australia).
Drug candidates Zygel (cannabidiol) and Lenabasum are being developed by US biopharmaceutical companies Zynerba Pharma and Corbus Pharma, respectively, and are expected to launch in the US and 5EU markets in 2021.
Magdalene Crabbe, Pharmaceutical Analyst at GlobalData, comments:
“Both Zygel and Lenabasum were granted fast track and orphan drug designation by the US Food and Drug Administration (FDA), and are expected to generate sales of $417m and $771m in 2025, respectively. Contributing to the high sales figures for these late-stage pipeline agents is the fact that Zygel and Lenabasum are both being developed to treat multiple disorders from a variety of therapy areas, including genetic disorders, musculoskeletal conditions, and autoimmune diseases.”
Take advantage of the infancy of this market and allow your company to get ahead of the competition in 2020 with our report, click ‘Buy Now’ to purchase this thematic research.